BIOVF - Swedish Orphan Biovitrum AB (publ) (BIOVF) Q2 2024 Earnings Call Transcript

2024-07-16 12:20:29 ET

Swedish Orphan Biovitrum AB (publ) (BIOVF)

Q2 2024 Earnings Conference Call

July 16, 2024, 08:00 AM ET

Company Participants

Guido Oelkers - Chief Executive Officer

Henrik Stenqvist - Chief Financial Officer

Lydia Abad-Franch - Head, R&D and Chief Medical Officer

Armin Reininger - Senior Scientific Advisor

Conference Call Participants

Brian Balchin - Jefferies

Viktor Sundberg - Nordea

Mattias Häggblom - Handelsbanken

Alistair Campbell - RBC

Harry Gillis - Berenberg

Christopher Uhde - SEB

Erik Hultgård - Carnegie

Niall Alexander - DB

Yifeng Liu - HSBC

Presentation

Operator

Ladies and gentlemen, welcome to the Q2 2024 Report Conference Call and Live Webcast. I am Sandra, the Chorus Call operator. I would like to remind you that all participants are in listen-only mode and the conference is being recorded. The presentation will be followed by a Q&A session. [Operator Instructions] The conference must not be recorded for publication or broadcast.

At this time, it's my pleasure to hand over to Guido Oelkers, CEO. Please go ahead, sir.

Guido Oelkers

Thank you. Hello, everyone. This is Guido Oelkers, CEO of Sobi. We are delighted to welcome you to the second quarter 2024 conference call for investors and analysts.

We posted this presentation to sobi.com earlier today. We would like to remind you, please go to Slide #2, of the usual provisions on statements about expectations and projections of future events. And unless stated otherwise, we will be making comments that mostly relate to the second quarter at constant exchange rate in million Swedish krona.

Please turn to Slide #3. Today, we plan to cover the key aspects of our Q2 report. I'm joined by Henrik Stenqvist, our CFO; Lydia Abad-Franch, our Head of R&D and Chief Medical Officer. During the Q&A sessions, we will be joined by Armin Reininger, our Senior Scientific Advisor, as well. We plan to review the presentation first and then have a Q&A until around 03:00 p.m. Swedish time. For those on the phone, please join the queue for questions by pressing star, one. We propose to ask only one or maximum two questions at a time.

With this said, let's go right to the beef of the presentation. Please turn to Slide #4. We are very pleased with the performance in the second quarter and overall strong first half, which has been driven by successfully executing on our strategy and growth of our strategic portfolio. We saw significant top-line growth of 11% in Q2 and an EBITA margin adjusted-for was 28%. Please bear in mind that we consolidated the business to [0:08:07.7] Fosun. Taking away this effect, our top-line growth would have been 26%....

For further details see: